203 related articles for article (PubMed ID: 30676731)
21. HIF-1-mediated activation of transferrin receptor gene transcription by iron chelation.
Bianchi L; Tacchini L; Cairo G
Nucleic Acids Res; 1999 Nov; 27(21):4223-7. PubMed ID: 10518614
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and biological properties of iron chelators based on a bis-2-(2-hydroxy-phenyl)-thiazole-4-carboxamide or -thiocarboxamide (BHPTC) scaffold.
Rodriguez-Lucena D; Gaboriau F; Rivault F; Schalk IJ; Lescoat G; Mislin GL
Bioorg Med Chem; 2010 Jan; 18(2):689-95. PubMed ID: 20036563
[TBL] [Abstract][Full Text] [Related]
23. Deferoxamine promotes MDA-MB-231 cell migration and invasion through increased ROS-dependent HIF-1α accumulation.
Liu Y; Cui Y; Shi M; Zhang Q; Wang Q; Chen X
Cell Physiol Biochem; 2014; 33(4):1036-46. PubMed ID: 24732598
[TBL] [Abstract][Full Text] [Related]
24. Deferoxamine enhances neovascularization and accelerates wound healing in diabetic rats via the accumulation of hypoxia-inducible factor-1α.
Hou Z; Nie C; Si Z; Ma Y
Diabetes Res Clin Pract; 2013 Jul; 101(1):62-71. PubMed ID: 23726275
[TBL] [Abstract][Full Text] [Related]
25. Deferoxamine released from poly(lactic-co-glycolic acid) promotes healing of osteoporotic bone defect via enhanced angiogenesis and osteogenesis.
Jia P; Chen H; Kang H; Qi J; Zhao P; Jiang M; Guo L; Zhou Q; Qian ND; Zhou HB; Xu YJ; Fan Y; Deng LF
J Biomed Mater Res A; 2016 Oct; 104(10):2515-27. PubMed ID: 27227768
[TBL] [Abstract][Full Text] [Related]
26. Desferrioxamine, an iron chelator, enhances HIF-1alpha accumulation via cyclooxygenase-2 signaling pathway.
Woo KJ; Lee TJ; Park JW; Kwon TK
Biochem Biophys Res Commun; 2006 Apr; 343(1):8-14. PubMed ID: 16527254
[TBL] [Abstract][Full Text] [Related]
27. Synthesis and characterization of quinoline-based thiosemicarbazones and correlation of cellular iron-binding efficacy to anti-tumor efficacy.
Serda M; Kalinowski DS; Mrozek-Wilczkiewicz A; Musiol R; Szurko A; Ratuszna A; Pantarat N; Kovacevic Z; Merlot AM; Richardson DR; Polanski J
Bioorg Med Chem Lett; 2012 Sep; 22(17):5527-31. PubMed ID: 22858101
[TBL] [Abstract][Full Text] [Related]
28. Cell cycle-dependent inhibition of the proliferation of human neural tumor cell lines by iron chelators.
Renton FJ; Jeitner TM
Biochem Pharmacol; 1996 Jun; 51(11):1553-61. PubMed ID: 8630097
[TBL] [Abstract][Full Text] [Related]
29. Deferoxamine induces prolonged cardiac preconditioning via accumulation of oxygen radicals.
Dendorfer A; Heidbreder M; Hellwig-Bürgel T; Jöhren O; Qadri F; Dominiak P
Free Radic Biol Med; 2005 Jan; 38(1):117-24. PubMed ID: 15589380
[TBL] [Abstract][Full Text] [Related]
30. Iron chelators deferoxamine and diethylenetriamine pentaacetic acid induce apoptosis in ovarian carcinoma.
Brard L; Granai CO; Swamy N
Gynecol Oncol; 2006 Jan; 100(1):116-27. PubMed ID: 16203029
[TBL] [Abstract][Full Text] [Related]
31. Iron chelation therapy.
Hershko CM; Link GM; Konijn AM; Cabantchik ZI
Curr Hematol Rep; 2005 Mar; 4(2):110-6. PubMed ID: 15720959
[TBL] [Abstract][Full Text] [Related]
32. A novel iron chelator that does not induce HIF-1 activity.
Creighton-Gutteridge M; Tyrrell RM
Free Radic Biol Med; 2002 Aug; 33(3):356-63. PubMed ID: 12126757
[TBL] [Abstract][Full Text] [Related]
33. In vivo efficacy, toxicity and biodistribution of ultra-long circulating desferrioxamine based polymeric iron chelator.
Hamilton JL; Imran Ul-Haq M; Abbina S; Kalathottukaren MT; Lai BF; Hatef A; Unniappan S; Kizhakkedathu JN
Biomaterials; 2016 Sep; 102():58-71. PubMed ID: 27322959
[TBL] [Abstract][Full Text] [Related]
34. Subcellular distribution of desferrioxamine and hydroxypyridin-4-one chelators in K562 cells affects chelation of intracellular iron pools.
Hoyes KP; Porter JB
Br J Haematol; 1993 Oct; 85(2):393-400. PubMed ID: 8280612
[TBL] [Abstract][Full Text] [Related]
35. Triptolide suppresses proliferation, hypoxia-inducible factor-1α and c-Myc expression in pancreatic cancer cells.
Ding X; Zhou X; Jiang B; Zhao Q; Zhou G
Mol Med Rep; 2015 Sep; 12(3):4508-4513. PubMed ID: 26094625
[TBL] [Abstract][Full Text] [Related]
36. Induction of hypoxia inducible factor (HIF-1α) in rat kidneys by iron chelation with the hydroxypyridinone, CP94.
Baek JH; Reiter CE; Manalo DJ; Buehler PW; Hider RC; Alayash AI
Biochim Biophys Acta; 2011; 1809(4-6):262-8. PubMed ID: 21558026
[TBL] [Abstract][Full Text] [Related]
37. Deferasirox, a novel oral iron chelator, shows antiproliferative activity against pancreatic cancer in vitro and in vivo.
Harima H; Kaino S; Takami T; Shinoda S; Matsumoto T; Fujisawa K; Yamamoto N; Yamasaki T; Sakaida I
BMC Cancer; 2016 Aug; 16(1):702. PubMed ID: 27582255
[TBL] [Abstract][Full Text] [Related]
38. Iron chelation by clinically relevant anthracyclines: alteration in expression of iron-regulated genes and atypical changes in intracellular iron distribution and trafficking.
Xu X; Sutak R; Richardson DR
Mol Pharmacol; 2008 Mar; 73(3):833-44. PubMed ID: 18029550
[TBL] [Abstract][Full Text] [Related]
39. Chelation of thallium by combining deferasirox and desferrioxamine in rats.
Saljooghi AS; Babaie M; Mendi FD; Zahmati M; Saljooghi ZS
Toxicol Ind Health; 2016 Jan; 32(1):83-8. PubMed ID: 24021432
[TBL] [Abstract][Full Text] [Related]
40. Effect of iron chelators on placental uptake and transfer of iron in rat.
Wong CT; McArdle HJ; Morgan EH
Am J Physiol; 1987 May; 252(5 Pt 1):C477-82. PubMed ID: 3578500
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
